Interní Med. 2012; 14(5): 235-238

Clinical aspects of treatment of essential hypertension with calcium channel blockers: what is the place of lercanidipine?

MUDr.Antonín Mandovec
Kardiologická a interní ambulance, Hořovice

Lercanidipine is a drug from a class of dihydropyridin calcium channel blockers, approved in the Czech Republic in treatment of

arterial hypertension. Calcium channel blockers together with ACE-inhibitors, AT1-blockers, diuretics and beta-blockers are drugs

of a first choice in the treatment of arterial hypertension. Regardless the initial problems are calcium channel blockers very well

estabilished in the treatment of arterial hypertension, and at the present era of „drug-specific“ and combined therapy of arterial

hypertension plays an important role. The aim of this article is show the practical aspects of lercanidipine use in the treatment of

arterial hypertension.

Keywords: hypertension, antihypertensive drugs, dihydropyridines, lercanidipine, efficacy, tolerability

Published: May 14, 2012  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Mandovec A. Clinical aspects of treatment of essential hypertension with calcium channel blockers: what is the place of lercanidipine? Interní Med. 2012;14(5):235-238.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Vasan R, Larson MG, Leip EP, et al. Assessment of frequency of progression to hypertension in non-hypertensive participants in the Framingham Heart Study: a cohort study. Lancet 2001; 358: 1682-1686. Go to original source... Go to PubMed...
    2. Widimský J, Cífkova R, Špinar J, et al. Doporučení diagnostických a léčebných postupů u arteriálni hypertenze - verze 2007. Cor Vasa 2008; 50(1): Kardio K3-K16.
    3. Staessen JA, Gasowski J, Wang JG, et al. Treatment of hypertension in the prevention and management of ischemic heart disease. J Hypertens. 2003; 21(6): 1055-1076. Go to original source... Go to PubMed...
    4. Lindholm LH, Carlberg B, Samuelsson O. Should beta-blockers remain first choice in the treatment of primary hypertension? A meta-analysis. Lancet 2005; 366: 1545-1553. Go to original source... Go to PubMed...
    5. Law MR, Morris JK, Wald NJ. Use of Blood Pressure Lowering Drugs in the Prevention of Cardiovascular Disease: Metaanalysis of 147 Randomised Trials in the Context of Expectations from Prospective Epidemiological Studies. BMJ. 2009; 338 (b1665).
    6. Mourad JJ, Bertrand M. Impact of antihypertensive treatment on mortality: A late-break analysis of recent clinical trials in hypertension. Abstract ESC 2010. Go to original source...
    7. Sever PS, Messerli FH. Hypertension management 2011: optimal combination therapy. Eur Heart J. 2011; 32(20): 2499-2506. Go to original source... Go to PubMed...
    8. Borghi C. Lercanidipine in hypertension. Vascular Health and Risk Management. 2005; (3): 173-182.
    9. Millar-Craig M, Shaffu B, Greenough A, et al. Lercanidipine vs lacidipine in isolated systolic hypertension. Journal of Human Hypertension. 2003; (17): 799-806. Go to original source... Go to PubMed...
    10. Barrios V, Escobar C, Calderón A, et al. The effectiveness and tolerability of lercanidipine is independent of body mass index or body fat percent. The LERZAMIG study. Br J Cardiol 2006; 13: 434-440.
    11. Dalla Vestra M, Pozza G, Mosca A, et al. Effect of lercanidipine compared with ramipril on albumin excretion rate in hypertensive type 2 diabetic patients with microalbuminuria: DIAL study. Diabetes Nutr Metab. 2004; 17(5): 259-266.
    12. Robles NR, Ocon J, Gomez CF, et al. Lercanidipine in patients with chronic renal failure: the ZAFRA study. Ren Fail. 2005; 27(1): 73-80. Go to original source... Go to PubMed...
    13. Cicero AF, Gerocarni B, Rosticci M, et al. Blood Pressure and Metabolic Effect of a Combination of Lercanidipine with Different Antihypertensive Drugs in Clinical Practice. Clin Exp Hypertens. 2011 Oct 3. [Epub ahead of print]. Go to original source... Go to PubMed...
    14. Barrios V, Escobar C, Navarro, A, et al. Lercanidipine is an effective and well tolerated antihypertensive drug regardless the cardiovascular risk profile: the LAURA Study. Int J Clin Pract. 2006; 60(11): 1364-1370. Go to original source... Go to PubMed...
    15. Leonetti G, Magnani B, Pessina AC, et al, on behalf of the COHORT Study Group: Tolerability of long-term treatment with lercanidipine vs. amlodipine and lacidipine in elderly hypertensives. Am J Hypertens 2002; 15; 932-940. Go to original source... Go to PubMed...
    16. Barrios V, Navarro A, Esteras A, et al. Antihypertensive efficacy and tolerability of lercanidipine in daily clinical practice. The ELYPSE Study. Eficacia de Lercanidipino y su Perfil de Seguridad. Blood Press. 2002; 11(2): 95-100. Go to original source... Go to PubMed...
    17. Romito R, Pansini MI, Perticone F, et al. Comparative Effect of Lercanidipine, Felodipine, and Nifedipine GITS on Blood Pressure and Heart Rate in Patients With Mild to Moderate Arterial Hypertension: The Lercanidipine in Adults (LEAD) Study. The Journal of Clinical Hypertension, 2003; 5(4): 249-253. Go to original source... Go to PubMed...
    18. Lund-Johansen P, Stranden E, Helberg S, et al. Quantification of leg oedema in postmenopausal hypertensive patients treated with lercanidipine or amlodipine. J Hypertens. 2003 May; 21(5): 1003-1010. Go to original source... Go to PubMed...
    19. Hollenberg NK. Observations on the safety of lercanidipine: adverse event data from placebo-controlled trials. Am J Hypertens 2002; 15: 58A-59A. Go to original source...
    20. Hadjipavlou G, Hafeez A, Messer B, et al. Management of lercanidipine overdose with hyperinsulinaemic euglycaemia therapy: case report. Scandinwavian Journal of Trauma, Resuscitation and Emergency Medicine 2011; 19: 8. Go to original source... Go to PubMed...
    21. Burnier M, Pruijm M, Wuerzner G. Treatment of essential hypertension with calcium channel blockers: what is the place of lercanidipine? Expert Opin Drug Metab Toxicol. 2009; 5(8): 981-987. Go to original source... Go to PubMed...

    Return to the content


    Internal Medicine for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.